¶ Locus Coeruleus
¶ Introduction
Locus Coeruleus is an important component in the neurobiology of neurodegenerative [diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases. This page provides detailed information about its structure, function, and role in disease processes.
¶ Overview
The locus coeruleus (LC) is a small, bilateral pigmented nucleus located in the dorsal pontine tegmentum of the [brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem--TEMP--/brain-regions)--FIX--. Its name, Latin for "blue spot," reflects the distinctive blue-gray color imparted by [neuromelanin] pigment that accumulates in its noradrenergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- over a lifetime (Berridge & Waterhouse, 2003). As the principal source of norepinephrine (noradrenaline) in the central nervous system, the LC's remarkably widespread projections influence nearly every major brain region, regulating arousal, attention, stress responses, memory consolidation, and autonomic function.
Critically, the LC is among the earliest brain structures to show pathological changes in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, and other neurodegenerative disorders, making it a central hub for understanding disease initiation and progression (Simic et al., 2021). Recent advances in neuromelanin-sensitive MRI now enable in vivo quantification of LC integrity, opening new avenues for early diagnosis and biomarker development (Betts et al., 2019).
¶ Anatomy and Connectivity
The locus coeruleus is a compact nucleus containing approximately 22,000-51,000 [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- per side in the adult human brain (total ~50,000-100,000 bilaterally), though estimates vary by quantification method (Mouton et al., 1994). Despite its small size, its efferent projections are among the most widespread of any brain nucleus.
¶ Afferent (Input) Connections
The LC integrates signals from diverse [brain regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/brain-regions:
-
[Prefrontal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--: Top-down cognitive control and task-related signals (Aston-Jones & Cohen, 2005)
-
[amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala--TEMP--/brain-regions)--FIX--: Emotional salience and threat processing
-
[hypothalamus[/brain-regions/[hypothalamus[/brain-regions/[hypothalamus[/brain-regions/[hypothalamus[/brain-regions/[hypothalamus--TEMP--/brain-regions)--FIX--: Stress signals via corticotropin-releasing factor (CRF) and homeostatic regulation
-
Nucleus paragigantocellularis: Autonomic and visceral information
-
Nucleus tractus solitarius: Visceral sensory input (vagal afferents)
-
Raphe nuclei: Serotonergic modulation
-
Ventral tegmental area: Dopaminergic input
-
Spinal cord: Somatosensory and nociceptive signals
¶ Efferent (Output) Projections
LC noradrenergic axons project to virtually the entire neuraxis:
-
Entire cerebral [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--: Diffuse noradrenergic innervation modulating cortical excitability and signal-to-noise ratio (Sara, 2009)
-
[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--: Memory consolidation, synaptic plasticity, and long-term potentiation
-
[amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala--TEMP--/brain-regions)--FIX--: Emotional memory encoding and fear conditioning
-
[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus--TEMP--/brain-regions)--FIX--: Sensory gating and arousal regulation
-
[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX--: Motor learning and coordination
-
[basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX--: Modulation of motor and reward circuits
-
[Entorhinal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--: Memory-related processing
-
Spinal cord: Autonomic regulation and pain modulation
¶ Topographic Organization
Recent research has revealed that, contrary to earlier views of the LC as a homogeneous nucleus, it contains functionally distinct subpopulations organized by projection target, neurotransmitter co-expression, and firing properties (Schwarz & Luo, 2015). Anterior LC [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- preferentially project to motor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, while posterior [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- innervate the [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- and [entorhinal cortex[/brain-regions/[entorhinal-cortex[/brain-regions/[entorhinal-cortex[/brain-regions/[entorhinal-cortex[/brain-regions/[entorhinal-cortex--TEMP--/brain-regions)--FIX--. This modular architecture has implications for the selective vulnerability patterns seen in different neurodegenerative diseases.
¶ Neurochemistry
¶ Norepinephrine System
The LC synthesizes norepinephrine (NE) from [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- via dopamine beta-hydroxylase (DBH). NE acts on adrenergic receptors throughout the brain:
-
Alpha-1 receptors: Excitatory; enhance neuronal responsiveness
-
Alpha-2 receptors: Inhibitory (including LC autoreceptors that provide negative feedback)
-
Beta-1 and Beta-2 receptors: Diverse modulatory effects on synaptic plasticity, metabolism, and [glial] function
¶ Firing Modes
LC neuronal activity alternates between two modes (Aston-Jones & Cohen, 2005):
-
Tonic mode: Sustained baseline firing (0.5-5 Hz) during wakefulness; promotes general arousal and scanning
-
Phasic mode: Brief high-frequency bursts (10-20 Hz, duration ~200 ms) in response to salient stimuli; promotes focused attention and task performance
-
Sleep states: LC [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- are minimally active during NREM sleep and virtually silent during REM sleep
¶ Co-transmitters
LC [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- co-release several neuropeptides:
-
Galanin: Co-stored in ~80% of human LC [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--; modulates noradrenergic transmission and may be neuroprotective
-
Neuropeptide Y (NPY): Anxiolytic and anti-stress functions
-
Brain-derived neurotrophic factor (BDNF): Neurotrophic support
¶ Neuromelanin
LC [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- progressively accumulate [neuromelanin], a dark pigment formed from oxidized catecholamines (primarily norepinephrine and dopamine). Neuromelanin has dual roles: it chelates potentially toxic metals (iron, copper) and reactive metabolites, but when released from degenerating [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, it activates [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--
/doi.org/10.1016/j.neubiorev.2016.09.023)).
¶ Role in Neurodegenerative Diseases
¶ Alzheimer's Disease
The LC is among the first brain regions to develop pathology in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--:
Early [Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- Pathology: Tau(/proteins/tau neurofibrillary tangles appear in the LC at Braak stage 0/I, decades before cortical involvement and clinical symptoms (Braak & Del Tredici, 2011). Pretangle tau] species (hyperphosphorylated but non-fibrillar) are detectable in the LC as early as the first decade of life in some individuals.
Progressive Neuronal Loss: LC neuronal loss in AD ranges from 30-80% depending on disease stage, correlating with cognitive decline, particularly attention and executive function deficits (Simic et al., 2021).
Consequences of LC Degeneration:
-
Noradrenergic deficit: Reduced NE in cortical and limbic targets impairs attention, arousal, and memory
-
Loss of anti-inflammatory tone: NE normally suppresses microglial/cell-types/microglia(). A 2025 study revealed heterogeneous damage patterns of the LC and [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX-- across AD subtypes (Tang et al., 2025).
¶ Parkinson's Disease
The LC is severely affected in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, with pathology often preceding [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX-- involvement:
-
[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein[/mechanisms/[alpha-synuclein--TEMP--/mechanisms)--FIX-- pathology: [Lewy bodies] and Lewy neurites in LC [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- are among the earliest [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- deposits (Braak PD stage 2)
-
Neuronal loss: Exceeds 50-80% in advanced PD, often more severe than substantia nigra loss
-
Non-motor symptoms: LC degeneration drives many non-motor features of PD:
-
Depression and anxiety (noradrenergic deficit in limbic circuits)
-
Cognitive impairment and executive dysfunction
-
Orthostatic hypotension (impaired autonomic regulation)
-
REM sleep behavior disorder (disinhibition of REM atonia circuits)
-
Fatigue and apathy
A 2024 DTI study showed that microstructural integrity of LC tracts to [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, [prefrontal cortex[/brain-regions/[prefrontal-cortex[/brain-regions/[prefrontal-cortex[/brain-regions/[prefrontal-cortex[/brain-regions/[prefrontal-cortex--TEMP--/brain-regions)--FIX--, and motor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- reflects [noradrenergic degeneration] in both AD and PD (Lin et al., 2024).
¶ Multiple System Atrophy
Severe LC degeneration is a hallmark of [MSA[/diseases/[msa[/diseases/[msa[/diseases/[msa[/diseases/[msa--TEMP--/diseases)--FIX--:
-
Contributes to profound autonomic dysfunction (orthostatic hypotension, urinary dysfunction)
-
Correlates with disease severity and rate of progression
-
Distinct pattern of cell loss compared to PD
¶ Progressive Supranuclear Palsy
Moderate LC neuronal loss occurs in [PSP[/diseases/[psp[/diseases/[psp[/diseases/[psp[/diseases/[psp--TEMP--/diseases)--FIX--:
-
Contributes to executive dysfunction, apathy, and disinhibition
-
Tau pathology in LC [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (4R tauopathy distinct from AD 3R/4R tau
-
Falls and postural instability may partly reflect noradrenergic deficits
¶ Lewy Body Dementia
In [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX--, LC degeneration is extensive:
-
alpha-synuclein deposits are prominent
-
Contributes to fluctuating attention and arousal (a cardinal feature)
-
Drives sleep disturbances and REM sleep behavior disorder
¶ Clinical Implications
¶ Therapeutic Strategies Targeting the LC-NE System
Several approaches aim to restore or compensate for noradrenergic deficits:
-
Norepinephrine reuptake inhibitors (NRIs): Atomoxetine has been tested in AD [clinical trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/clinical-trials. A 2019 randomized controlled trial showed that atomoxetine reduced CSF tau] and improved LC-dependent cognitive functions in MCI patients (Levey et al., 2022).
-
Alpha-2 adrenergic modulators: Guanfacine and clonidine modulate LC output; guanfacine has shown cognitive benefits in preclinical AD models
-
[Cholinesterase inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors--TEMP--/entities)--FIX--: Some benefit may derive from indirect modulation of LC-NE circuits
-
Exercise: Physical activity robustly activates the LC-NE system and is associated with reduced AD risk
-
Vagus nerve stimulation: Activates LC via vagal afferents; being explored for cognitive enhancement
¶ Biomarker Potential
The LC is emerging as a promising [neuroimaging[/diagnostics/[neuroimaging[/diagnostics/[neuroimaging[/diagnostics/[neuroimaging[/diagnostics/[neuroimaging--TEMP--/diagnostics)--FIX-- biomarker target:
-
Neuromelanin-sensitive MRI (NM-MRI): Enables in vivo quantification of LC integrity. LC signal intensity correlates with neuronal density and declines with disease progression in AD and PD (Betts et al., 2019).
-
LC tract integrity (DTI/DWI): Diffusion tensor imaging of LC projection tracts reflects noradrenergic degeneration (Lin et al., 2024)
-
CSF norepinephrine metabolites: MHPG (3-methoxy-4-hydroxyphenylglycol) levels reflect central noradrenergic activity
-
Pupillometry: LC-mediated pupil dilation responses serve as a non-invasive proxy for LC function
¶ Early Diagnostic Potential
Given that LC pathology precedes clinical symptoms by decades in AD, LC-based biomarkers may enable ultra-early detection of neurodegeneration. A 2025 review highlighted the LC as "a blue spot for early diagnosis and prognosis of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--" (Frontiers in Aging Neuroscience, 2025).
¶ Sleep, Arousal, and Cognition
¶ Arousal Regulation
The LC is central to the ascending arousal system:
-
Wakefulness: High tonic LC activity maintains cortical activation and behavioral readiness
-
NREM sleep: LC [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- reduce firing, permitting cortical synchronization
-
REM sleep: LC [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- are virtually silent, allowing cholinergic systems to drive REM phenomena
-
Sleep-wake transitions: LC activation is one of the first neural events during awakening
¶ Cognitive Functions
The LC-NE system optimizes cognitive performance through:
-
Attention: Phasic LC responses enhance processing of salient stimuli (signal-to-noise optimization)
-
Working memory: NE modulation of [prefrontal cortex[/brain-regions/[prefrontal-cortex[/brain-regions/[prefrontal-cortex[/brain-regions/[prefrontal-cortex[/brain-regions/[prefrontal-cortex--TEMP--/brain-regions)--FIX-- via alpha-2A receptors
-
Memory consolidation: NE enhances [hippocampal] long-term potentiation and emotional memory encoding
-
Cognitive flexibility: LC mode-switching between focused (phasic) and exploratory (tonic) states (Aston-Jones & Cohen, 2005)
¶ Stress Response
The LC-NE system is a critical mediator of the central stress response:
-
CRF from the [hypothalamus[/brain-regions/[hypothalamus[/brain-regions/[hypothalamus[/brain-regions/[hypothalamus[/brain-regions/[hypothalamus--TEMP--/brain-regions)--FIX-- and [amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala--TEMP--/brain-regions)--FIX-- activates LC [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
-
Stress-induced LC hyperactivity increases NE release throughout the brain
-
Chronic stress can damage LC [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and accelerate neurodegeneration
¶ Background
The study of Locus Coeruleus has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
¶ External Links
-
PubMed - Biomedical literature
-
Alzheimer's Disease Neuroimaging Initiative - Research data
-
Allen Brain Atlas - Brain gene expression data
¶ Brain Atlas Resources
This section links to atlas resources relevant to this brain region.
- Allen Human Brain Atlas: Locus Coeruleus expression search
- Allen Mouse Brain Atlas: Locus Coeruleus search
- Allen Cell Type Atlas: Transcriptomic cell type reference
- BrainSpan Developmental Transcriptome: Locus Coeruleus developmental expression
¶ See Also
- [Microglia[/alpha-synuclein (α[-Syn[/alpha-synuclein (α[-Syn[/alpha-synuclein (α[-Syn[/alpha-synuclein (α[-Syn[/alpha-synuclein (α[-Syn[/alpha-synuclein (α[-Syn[/alpha-synuclein (α[-Syn[/alpha-synuclein (α[-Syn](/alpha-synuclein (α-Syn)[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--)
¶ Research Evidence
¶ Spatial transcriptomics validation using EEL-FISH on midbrain and hindbrain tissue sections
Confirmed RNA-seq findings spatially. Dopaminergic cells demarcated PBP, SN, and VTA. GABAergic cells distinguished SN pars compacta vs reticulata. Glutamatergic PVALB+ cells occupied red and pontine nuclei. Noradrenergic cells marked locus coeruleus. Spatial distributions matched RNA-seq clusters for lower rhombic lip neurons and CALB2+ dopaminergic cells. Revealed combinatorial neuropeptide and neurotransmitter expression patterns.
Model System: Fresh-frozen human postmortem brain tissue sections from midbrain and hindbrain regions
Statistical Significance: N/A
¶ This is primarily a review paper synthesizing existing literature on amygdala involvement in Alzheimer's disease. The paper references novel human functional connectivity data from Grande et al. (2022) using 7T MRI, showing connectivity between amygdala and anterior hippocampus
The amygdala shows early NFT accumulation (from stage II), particularly in the inferior-medial domain. There is strong connectivity between amygdala and anterior hippocampus, entorhinal cortex, and locus coeruleus. The amygdala may serve as an alternative pathway for NFT spreading in the MTL. Early amygdala involvement is linked to neuropsychiatric symptoms in AD.
Model System: Human subjects (young individuals for functional connectivity; various Alzheimer cohorts)
Statistical Significance: Not applicable for review paper; referenced studies reported various p-values (e.g., FWE P < 0.05 for functional connectivity)
¶ Review of human postmortem brain studies examining locus coeruleus (LC) neuronal loss and volume changes across Alzheimer's disease progression
LC neuronal loss averages 63% in AD; LC volume decreases by 8.4% per Braak stage increase; 8% of LC neurons are p-tau-positive at Braak stage 0, doubling by Braak stage I, reaching 100% by Braak stage VI; rostral portion affected more severely (83% loss) compared to middle (23%) and caudal (15%) parts
Model System: Human postmortem brain tissue
Statistical Significance: Significant correlation between LC volume loss and Braak stage (p<0.05)
¶ References
- [Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Rev. 2003;42(1):33-84. DOI
- [Simic G, Babic Leko M, Wray S, et al. Locus coeruleus as the hub of neurodegenerative processes in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--. Prog Brain Res. 2021;262:373-400. DOI
- [Braak H, Del Tredici K. The pathological process underlying [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- in individuals under thirty. Acta Neuropathol. 2011;121(2):171-181. DOI
- [Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci. 2005;28:403-450. DOI
- [Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci. 2009;10(3):211-223. DOI
- [Schwarz LA, Luo L. Organization of the locus coeruleus-norepinephrine system. Curr Biol. 2015;25(21):R1051-R1056. DOI
- [Mouton PR, Pakkenberg B, Gundersen HJ, Price DL. Absolute number and size of pigmented locus coeruleus [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in young and aged individuals. J Chem Neuroanat. 1994;7(3):185-190. DOI
- [Betts MJ, Kirilina E, Otaduy MCG, et al. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain. 2019;142(9):2558-2571. DOI
- [Zucca FA, Segura-Aguilar J, Ferrari E, et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--. Prog Neurobiol. 2017;155:96-119. DOI
- [Lin YS, Vetter C, et al. Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer's Disease and [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--. Transl Neurodegener. 2024;13:9. DOI
- [Galgani A, et al. The degeneration of locus coeruleus occurring during Alzheimer's Disease clinical progression: a neuroimaging follow-up investigation. Brain Struct Funct. 2024;229:1573-1584. DOI
- [Tang Y, et al. Unraveling the complexity of neurodegeneration: heterogeneous damage patterns of locus coeruleus and substantia nigra in Alzheimer's Disease. Alzheimers Dement. 2025;21(3):e70605. DOI
- [Weinshenker D. Functional consequences of locus coeruleus degeneration in Alzheimer's Disease. Curr Alzheimer Res. 2008;5(3):342-345. DOI
- [Giorgi FS, Ryskalin L, Biagioni F, et al. The role of locus coeruleus in neuroinflammation occurring in Alzheimer's Disease. Brain Res Bull. 2017;131:93-106. DOI
- [Levey AI, Qiu D, Zhao L, et al. A phase II study repurposing atomoxetine for [neuroprotection[/treatments/[neuroprotection[/treatments/[neuroprotection[/treatments/[neuroprotection[/treatments/[neuroprotection--TEMP--/treatments)--FIX-- in [mild cognitive impairment[/diseases/[mci[/diseases/[mci[/diseases/[mci[/diseases/[mci--TEMP--/diseases)--FIX--. Brain. 2022;145(6):1924-1938. DOI
- [Fernandez-Cabello S, et al. The locus coeruleus, a blue spot for early diagnosis and prognosis of Alzheimer's Disease. Front Aging Neurosci. 2025;17:1632236. DOI
- [Ressler KJ, Nemeroff CB. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry. 1999;46(9):1219-1233. DOI
-
- [norepinephrine[/entities/[norepinephrine[/entities/[norepinephrine[/entities/[norepinephrine[/entities/[norepinephrine--TEMP--/entities)--FIX-- — Primary neurotransmitter of the locus coeruleus
-
- [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- — Disease with early LC neuronal loss and tau pathology
-
- [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- — Disease with LC degeneration contributing to non-motor symptoms
-
- Tau Pathology] — Tau NFTs accumulate early in the LC
-
- [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- — LC modulates neuroinflammatory responses
-
- [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- — Key target of LC noradrenergic projections